Ac-SDKP is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-04-20. Numbers and descriptions here follow the published literature rather than marketing material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Typical form for short synthetic peptides |
| Solubility class | Freely soluble in water and aqueous buffer | Dissolution aided by gentle mixing, not vigorous shaking |
| Typical storage temperature | −20 °C, desiccated | −80 °C used for long-term holding |
| Common analytical method | Reverse-phase HPLC with UV detection near 214 nm | Identity confirmed separately by mass spectrometry |
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming varies between suppliers and publications |
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
From the beginning of the Gaza war, reports emerged of children being killed and maimed. Children were also killed in Israeli airstrikes, including in areas designated as “safe zones” by the IDF. The numbers rose rapidly. During the first week of the war in October 2023, at least 447 children were killed. By 3 December 2023, the number had reached an estimated 6,150 children, rising to about an estimated 10,000 by mid-January 2024, with thousands more believed to be buried under rubble. Defense for Children International put the figure at 12,100 children in early February, and mid-April 2024 estimates cited around 14,500 fatalities. In May 2024, the United Nations adjusted its estimate down from 14,500 children to 7,797 identified child deaths, and by December 2024, the overall figure was again reported at roughly 14,500. By 3 September 2025, at least 19,424 children had been reported killed. In March 2024, the United Nations stated that more children had died in Gaza between October 2023 and February 2024 than the sum of all global conflicts from 2019 to 2022. Catherine M. Russell, the head of UNICEF, stated, "We haven’t seen that rate of death among children in almost any other conflict in the world". In late September 2024, Oxfam and Action on Armed Violence reported that the number of children killed in Gaza over the past year was the highest recorded in a single year for any conflict worldwide in the last 20 years.
Gingival curettage is a surgical procedure designed to remove the soft tissue lining of the periodontal pocket with a curet, leaving only a gingival connective tissue lining. ... Gingival curettage, as originally conceived, was designed to promote new connective tissue attachment to the tooth, by the removal of pocket lining and junctional epithelium. Since there is no evidence that gingival curettage has any therapeutic benefit in the treatment of chronic periodontitis, the American Dental Association has deleted that code from the fourth edition of Current Dental Terminology (CDT-4). In addition, the American Academy of Periodontology, in its Guidelines for Periodontal Therapy, did not include gingival curettage as a method of treatment. This indicates that the dental community as a whole regards gingival curettage as a procedure with no clinical value. Curettage is also a major method used for removing osteoid osteoma and osteoblastoma. Curettage with subsequent culture is more accurate than ulcer base swan culture or aspiration and culture for diabetic foot ulcers. Curettage is also used when excising a chalazion of the eyelid.
The gateway hypothesis is the idea that using less harmful drugs can lead to more harmful ones. Some users who begin by vaping will go on to also smoke traditional cigarettes. People with mental illnesses, who as a group are more susceptible to nicotine addiction, are at particularly high risk of dual use. The correlation between vaping and subsequent smoking does not necessarily imply a causal effect. Users may have underlying characteristics that predispose them to nicotine use. There is a genetic association between smoking, vaping, gambling, promiscuity, and risk-taking behaviors. Young people with poor executive function vape, smoke, and drink alcohol more than their peers. E-cigarette users are also more likely to use both cannabis and unprescribed Adderall or Ritalin. Longitudinal studies of e-cigarettes and smoking have been criticized for failing to adequately control for these and other confounding factors. Smoking rates have declined as e-cigarette use has grown, especially among young people. This may be because there is little gateway effect at the population level, or because of anti-smoking interventions.
Sources: en.wikipedia.org
== Relevance and contribution to omics == The aim of genomics is to study the genome, or the collection of genetic material in an organism. Genomics subfields, or other -omics, such as Transcriptomics and proteomics, aim to characterize genome function by quantifying products of the genome (such as RNA and proteins) under different conditions. In doing so, omics gain insight into different levels of regulation of gene expression and are therefore genome function. However, these fields characterize biomolecules that have already been formed. In some cases, RNA or protein abundance does not reflect function because these biomolecules may be degraded rapidly, or they may remain in a cell long after they are initially synthesized. When using proteomics techniques to study the proteome, regulation of protein abundance at the level of post-translational modification and protein degradation may obscure earlier regulatory processes. Because cellular functions are often regulated at the level of translation, meaning the transcriptome does not always reflect genome function, using translatomics techniques to study the translatome may allow one to observe regulation of genome function that would be obscured in transcriptomics or proteomics studies.
Worldwide: alcohol (beer, wine), vinegar, olives, yogurt, bread, cheese Asia East and Southeast Asia: amazake, atchara, belacan, burong mangga, com ruou, doenjang, douchi, fish sauce, lah pet, lambanog, kimchi, kombucha, leppet-so, narezushi, miso, nata de coco, nattō, ngapi, oncom, padaek, pla ra, prahok, ruou nep, sake, shrimp paste, soju, soy sauce, stinky tofu, tape, tempeh, tempoyak, zha cai Central Asia: kumis, kefir, shubat, qatiq (yogurt) South Asia: achar, appam, dosa, dhokla, dahi (yogurt), idli, mixed pickle, ngari, sinki, tongba, paneer Africa: garri, injera, laxoox, mageu, ogi, ogiri, iru Americas: chicha, chocolate, vanilla, hot sauce, tepache, tibicos, pulque, muktuk, kiviak, parakari Middle East: torshi, boza Europe: sourdough bread, elderberry wine, kombucha, pickling, rakfisk, sauerkraut, pickled cucumber, surströmming, mead, kvass, salami, sucuk, prosciutto, cultured milk products such as quark, kefir, filmjölk, crème fraîche, smetana, skyr, rakı, tupí, żur. Oceania: poi, kānga pirau
Wetsuits are economical and used where the water temperature is not too low - more than about 65 °F (18 °C), the diver will not be spending too long in the water, and the water is reasonably clean. Dry suits are better thermal protection than most wetsuits, and isolate the diver from the environment more effectively than other exposure suits. When diving in contaminated water, a drysuit with integral boots, sealed dry gloves and a helmet sealed directly to the suit provides the best environmental isolation. The suit material must be selected to be compatible with the expected contaminants. Thermal undersuits can be matched to the expected water temperature. Hot water suits provide active warming which is particularly suitable for use with helium based breathing gases. Heated water is provided from the surface through a hose in the umbilical, and water flow can be adjusted to suit the diver's needs. Heated water continuously flows into the suit and is distributed by perforated internal tubes down the front and back of the torso and along the limbs.
Sources: en.wikipedia.org
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.
Not necessarily. Some vendors use the name for the full 43-residue protein, while others apply it to a short actin-binding fragment or to a related tetrapeptide. The sequence should be confirmed from documentation rather than assumed from the label.
No thymosin beta-4 fragment holds marketing approval as a medicine in major jurisdictions. Material offered for sale is typically labelled for laboratory research only.
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.